Association of serum amyloid A protein and peptide fragments with prognosis in renal cancer

British Journal of Cancer

Volumn 103, Issue 1, 2010, Pages 101-111

  Wood, S L ^a   Rogers, M ^a   Cairns, D A ^a   Paul, A ^b   Thompson, D ^c   Vasudev, N S ^a   Selby, P J ^a   Banks, R E ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c Leeds General Inf Irmary ^*  (United Kingdom)

Author keywords

CRP; prognosis; proteomics; RCC; SAA; SELDI

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; PEPTIDE FRAGMENT; SERUM AMYLOID A;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ELECTROSPRAY; HUMAN; HUMAN CELL; IMMUNOASSAY; KIDNEY CARCINOMA; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEOMICS; QUALITY CONTROL; TIME OF FLIGHT MASS SPECTROMETRY; ADULT; AGED; BLOOD; DISEASE FREE SURVIVAL; FEMALE; KIDNEY TUMOR; MALE; MASS SPECTROMETRY; MIDDLE AGED; MORTALITY; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROGNOSIS; SERUM AMYLOID A PROTEIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SURVIVAL RATE;

EID: 77954177847     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605720     Document Type: Article

References (48)

1. Banks RE, Forbes MA, Storr M, Higginson J, Thompson D, Raynes J, Illingworth JM, Perren TJ, Selby PJ, Whicher JT (1995) The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 102: 217-223
2. Banks RE, Stanley AJ, Cairns DA, Barrett JH, Clarke P, Thompson D, Selby PJ (2005) Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin Chem 51(9): 1637-1649
3. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, Lijmer JG, Moher D, Rennie D, de Vet HC (2003) Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Clin Chem 49(1): 1-6
4. Cairns DA, Perkins DN, Stanley AJ, Thompson D, Barrett JH, Selby PJ, Banks RE (2009) Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics 9: 519
5. Cindolo L, De La Taille A, Messina G, Romis L, Abbou CC, Altieri V, Rodriguez A, Patard JJ (2003) A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92: 901-905
6. Ducret A, Bruun CF, Bures EJ, Marhaug G, Husby G, Aebersold R (1996) Characterization of human serum amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/electrospray ionization tandem mass spectrometry. Electrophoresis 17: 866-876
7. Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55: 851-863
8. Engwegen JY, Mehra N, Haanen JB, Bonfrer JM, Schellens JH, Voest EE, Beijnen JH (2007) Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab Invest 87(2): 161-172
9. Findeisen P, Neumaier M (2009) Mass spectrometry-based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin Chem Lab Med 47: 666-684
10. Findeisen P, Zapatka M, Peccerella T, Matzk H, Neumaier M, Schadendorf D, Ugurel S (2009) Serum amyloid A as a prognostic marker in melanoma identified by proteomic profiling. J Clin Oncol 13: 2199-2208
11. Galfano A, Novara G, Iafrate M, Cavalleri S, Martignoni G, Gardiman M, D'Elia C, Patard JJ, Artibani W, Ficarra V (2008) Mathematical models for prognostic prediction in patients with renal cell carcinoma. Urol Int 80: 113-123
12. Iimura Y, Saito K, Fujii Y, Kumagai J, Kawakami S, Komai Y, Yonese J, Fukui I, Kihara K (2009) Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on pre-operative serum C-reactive protein and TNM classification: the TNM-C score. J Urol 181: 1004-1012
13. Issaq HJ, Xiao Z, Veenstra TD (2007) Serum and plasma proteomics. Chem Rev 107: 3601-3620
14. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M (2006) Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int J Urol 13: 1365-1370
15. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C (2005) Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int 68: 2103-2110
16. Karakiewicz PI, Hutterer GC, Trinh QD, Jeldres C, Perrotte P, Gallina A, Tostain J, Patard JJ (2007) C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 110: 1241-1247
17. Karakiewicz PI, Suardi N, Capitanio U, Jeldres C, Ficarra V, Cindolo L, De La Taille A, Tostain J, Mulders PFA, Bensalah K, Artibani W, Salomon L, Zigeuner R, Valeri A, Descotes J-L, Rambeaud J-J, Mejean A, Montorsi F, Bertini R, Patard J-J (2009) A preoperative prognostic model for patients treated with nephrectomy for renal cell carcinoma. Eur Urol 55: 287-295
18. Kiehntopf M, Siegmund R, Deufel T (2007) Use of SELDI-TOF mass spectrometry for identification of new biomarkers: potetential and limitations. Clin Chem Lab Med 45: 1435-1449
19. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW (2003) Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 537: 166-170
20. Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Ohara-Mikami Y, Matsudo T, Takahashi K (2001) Significance of serum amyloid a on the prognosis in patients with renal cell carcinoma. Cancer 92(8): 2072-2075
21. Komai Y, Saito K, Sakai K, Morimoto S (2007) Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99: 77-80
22. Koomen JM, Haura EB, Bepler G, Sutphen R, Remily-Wood ER, Benson K, Hussein M, Hazlehurst LA, Yeatman TJ, Hildreth LT, Sellers TA, Jacobsen PB, Fenstermacher DA, Dalton WS (2008) Proteomic contributions to personalized cancer care. Mol Cell Proteomics 7: 1780-1794
23. Koomen JM, Li D, Xiao LC, Liu TC, Coombes KR, Abbruzzese J, Kobayashi R (2005) Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J Proteome Res 4(3): 972-981
24. Kosari F, Parker AS, Kube DM, Lohse CM, Leibovich BC, Blute ML, Cheville JC, Vasmatzis G (2005) Clear cell renal carcinoma: gene expression analyses identify a potential signature for tumour aggressiveness. Clin Cancer Res 11(14): 5128-5139
25. Lane BR, Kattan MW (2008) Prognostic models and algorithms in renal cell carcinoma. Urol Clin North Am 35: 613-625
26. Liaw A, Weiner M (2002) Classification and regression by randomForest. Rnews 2: 18-22
27. Liou LS, Shi T, Duan ZH, Sadhukhan P, Der SD, Novick AA, Hissong J, Skacel M, Almasan A, DiDonato JA (2004) Microarray gene expression profiling and analysis in renal cell carcinoma. BMC Urol 4: 9
28. Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 26: 427-435
29. Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute phase protein involved in tumour pathogenesis. Cell Mol Life Sci 66: 9-26
30. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 97(16): 1180-1184 (Pubitemid 41258223)
31. Munro NP, Cairns DA, Clarke P, Rogers M, Stanley AJ, Barrett JH, Harnden P, Thompson D, Eardley I, Banks RE, Knowles MA (2006) Urinary biomarker profiling in transitional cell carcinoma. Int J Cancer 119: 2642-2650
32. Paret C, Schön Z, Szponar A, Kovacs G (2010) Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur Urol 859-866
33. Peng J, Stanley AJ, Cairns D, Selby PJ, Banks RE (2009) Using the protein chip interface with quadrupole time-of-flight mass spectrometry to directly identify peaks in SELDI profiles-initial evaluation using low molecular weight serum peaks. Proteomics 9: 492-498
34. Raj GV, Thompson RH, Leibovich BC, Blute ML, Russo P, Kattan MW (2008) Preoperative nomogram predicting 12-year probability of metastatic renal cancer. J Urol 179: 2146-2151
35. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Loening SA, Jung K (2008) Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. Cancer Lett 269: 85-92
36. Ramsey S, Lamb GWA, Aitchison M, McMillan DC (2008) Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. Br J Urol 101: 959-963
37. Richter R, Schulz-Knappe P, Schrader M, Standker L, Jurgens M, Tammen H, Forssmann WG (1999) Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl 726(1-2): 25-35
38. Rini BI, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373: 1119-1132
39. Rocken C, Menard R, Buhling F, Vockler S, Raynes J, Stix B, Kruger S, Roessner A, Kahne T (2005) Proteolysis of serum amyloid A and AA amyloid proteins by cystine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis 64: 808-815
40. Rogers MA, Clarke P, Noble J, Munro NP, Paul A, Selby PJ, Banks RE (2003) Proteomic profiling of urinary proteins in renal cancer by surface enhanced laser desorption ionisation (SELDI) and neural network analysis: identification of key issues affecting potential clinical utility. Cancer Res 63(20): 6971-6983
41. Rouviere O, Bouvier R, Negrier S, Badet L, Lyonnet D (2006) Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up? Nat Clin Pract Oncol 3(4): 200-213
42. Stix B, Kahne T, Sletten K, Raynes J, Roessner A, Rocken C (2001) Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1,-2, and-3. Am J Pathol 159: 561-570
43. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, Humeny A, Kratzin H, Deeg M, Kuczyk M, Mueller GA, Mueller CA, Flad T (2004) Serum protein profiling by SELDI mass spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Lab Invest 84(7): 845-856
44. van der Hilst JCH, Kluve-Beckerman B, van der Meer JW, Simon A (2009) Cathepsin D activity protects against development of type AA amyloid fibrils. Eur J Clin Invest 39: 412-416
45. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P (2006) Differential exoprotease activities confer tumor-specific serum peptidome patterns. J Clin Invest 116(1): 271-284
46. Whelan LC, Power KAR, McDowell DT, Kennedy J, Gallagher WM (2008) Applications of SELDI-MS technology in oncology. J Cell Mol Med 12: 1535-1547
47. Young AC, Craven RA, Cohen D, Taylor C, Booth C, Harnden P, Cairns DA, Astuti D, Gregory W, Maher ER, Knowles MA, Joyce A, Selby PJ, Banks RE (2009) Analysis of VHL gene alterations and their relationship to clinical parameters in sporadic conventional renal cell carcinoma. Clin Cancer Res 15: 7582-7592
48. Zhou M, Prieto DA, Lucas DA, Chan KC, Issaq HJ, Veenstra TD, Conrads TP (2006) Identification of the SELDI ProteinChip human serum retentate by microcapillary liquid chromatography-tandem mass spectrometry. J Proteome Res 5: 2207-2216